A(A. V. Sitenkova (Bukhovets)

A. V. Sitenkova (Bukhovets)

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Sitenkova (Bukhovets) has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biopharmaceutical evaluation of oral controlled indomethacin delivery systems based on drug-polymer and drug-interpolyelectrolyte complexes

    by A. Yu. Sitenkov, A. V. Sitenkova (Bukhovets), S. F. Nasibullin, I. I. Semina, R. I. Moustafine

    Introduction. Interpolyelectrolyte complexes (IPEC) are promising carriers for controlled drug delivery systems. The introduction of ionic API into delivery systems can lead to the formation of bonds with polyelectrolytes, which affects the release of the drug from the dosage form. Previously, a drug-polymer complex (DPC) based on Eudragit® EPO with indomethacin, as well as an drug-interpolyelectrolyte complex (DIPEC) with the participation of copolymers of Eudragit® EPO, Eudragit® S100 and indomethacin were obtained. The physicochemical properties of the optimal samples were assessed and the prospects for their use in controlled delivery systems of indomethacin were shown. Aim. Comparative biopharmaceutical evaluation of drug-polymer and drug-interpolyelectrolyte complexes as oral controlled delivery systems for indomethacin. Materials and methods. Drug-polymer complex based on Eudragit® EPO and indomethacin (DPC EPO/IND) and druginterpolyelectrolyte complex based on Eudragit® EPO, Eudragit® S100 and indomethacin (DIPEC EPO/S100/IND) were obtained at the molar ratio of components of 3 : 1 and 4.5 : 1 : 1, respectively. The release of indomethacin from DPC and DIPEC powders and tablets was assessed by apparatus II "Rotating Paddle" using a DT 828 dissolution tester (ERWEKA GmbH, Germany). The concentration of indomethacin was determined by UV spectrophotometry on a Lambda 25 spectrophotometer (PerkinElmer, USA) at a wavelength of 270 nm. Mathematical modeling of indomethacin release was performed using Microsoft Excel Office. Pharmacokinetic studies were performed on Soviet Chinchilla rabbits. The studied samples were administered orally, blood samples were taken from the ear at certain intervals of time after administration. The concentration of indomethacin in blood plasma was determined by HPLC on an LC-20 Prominence chromatograph (Shimadzu, Japan) with UV-detection. The main pharmacokinetic parameters were calculated using the Thermo Kinetica® program (Version 5.0, Build 5.00.11; Thermo Fisher Scientific, USA). Results and discussion. The release profiles of indomethacin from DPC and DIPEC powders are characterized as "intestinal type", where the predominant mechanism is the process of relaxation of polymer chains during the release of the substance. The release of indomethacin from the tablet matrix based on DIPEC differs from the release profile from DIPEC powder and reaches 19 %. The release profile of indomethacin from DPC EPO/IND tablets is similar to the release profile from the powder and reaches 58 %. A hydrogel layer is formed on the surface of DIPEC tablets, which prevents the penetration of the dissolution medium into the matrix. The release of indomethacin from DIPEC EPO/S100/IND samples occurs due to the diffusion of the drug from the matrix. DPC and DIPEC in powder form have a longer mean retention time (MRT) compared to DPC and DIPEC tablets. MRT of DIPEC and DPC in powder form exceeds MRT of indomethacin substance by three and four times, respectively. Maximum concentration of indomethacin in blood plasma of rabbits after oral administration of DIPEC tablets is observed after 8 hours of the experiment. Conclusion. Indomethacin release from DPC EPO/IND occurs due to the presence of "defective" regions and relaxation of polymer chains, this ensures a slow release of the API and low relative bioavailability, which allows using DPC in indomethacin delivery systems for the treatment of inflammatory diseases of the colon. Tablet systems DIPEC EPO/S100/IND allow changing the release profile of indomethacin due to the diffusion processes of the substance through the formed hydrogel layer on the surface of the matrix, ensuring high bioavailability, can be used as matrix systems for delivering the API to the optimal absorption zone.

  • Open Access

    Development of Lyophilisates Based on Polymer-drug and Interpolyelectrolyte Complexes: Pharmacokinetic Assessment

    by V. R. Timergalieva, A. Yu. Sitenkov, A. V. Sitenkova (Bukhovets), E. S. Elizarova, D. S. Gordeeva, I. I. Semina, R. I. Moustafine

    Introduction. Orally dispersible dosage forms are one of the new trends in the field of drug delivery systems. One type of such dosage forms is oral lyophilisates that are obtained by freeze-drying a pre-prepared mixture containing the active pharmaceutical ingredient (API) and excipients. This dosage form provides immediate release of the active pharmaceutical ingredient in the oral cavity using a less amount of excipients.Aim. Pharmacokinetic studies of previously obtained lyophilisates based on the polymer-drug complex Eudragit® E PO / ibuprofen (PDC EPO-IB) and the interpolyelectrolyte complex (IPEC) Carbopol® Ultrez 10 / Eudragit® E PO (IPEC C10/EPO) and metronidazole.Materials and methods. Lyophilisates of the following compositions were obtained: 1) 100 mg of metronidazole and 50 mg of IPEC C10/EPO or 2) 100 mg of PDC EPO-IB, the first or second composition of the carrier with API was dispersed in 50 % maltodextrin syrup, Span®80 was added – 1.42 % from the total mass of the mixture. The mixture was poured into blisters for tablets, frozen in a FreeZone 1L laboratory dryer (Labconco, USA) for 24 hours at a temperature of –49 °C, and the main drying was carried out at a pressure of 0.350 mbar. Soviet Chinchilla rabbits were administered one lyophilisate containing PDC EPO/IB or IPEC C10/EPO with metronidazole; the substances ibuprofen (50 mg) and metronidazole (100 mg) were used as reference drugs. The concentration of API was determined by high-performance liquid chromatography (HPLC) on an LC-20 Prominence chromatograph (Shimadzu Corporation, Japan) with UV detection. Pharmacokinetic parameters were calculated using a model-independent method using the Thermo KinetikaTM (version 5.0, Build 5.00.11, Thermo Fisher Scientific, USA) program.Results and discussion. According to the obtained pharmacokinetic profiles, the maximum concentration of ibuprofen from EPO/IB PDC is achieved within the first hour after oral administration. The second peak in the profiles shows the absorption of the remaining portion of the API into the blood from the gastrointestinal tract (GIT), both in the case of EPO/IB PDC and in the case of ibuprofen from the substance. The relative bioavailability of EPO/IB PDC was Frel = 86.06 %. Lyophilisates based on IPEC C10/EPO provide the maximum concentration of metronidazole after 30 minutes (Cmax = 4.659 μg/ml). Relative bioavailability was Frel = 107.6 %.Conclusion. According to studies, the maximum concentration of ibuprofen and metronidazole is achieved within the first hour after oral administration of lyophilisates containing PDC EPO-IB and IPEC C10/EPO. Absorption of medicinal substances in the oral cavity occurs due to the components included in the dispersible dosage form, as well as due to the presence of a ЕРО copolymer, PDC and an IPEC, which are able to linger on the oral mucosa due to the presence of mucoadhesive properties. Thus, the pharmacokinetic studies of ibuprofen and metronidazole from the obtained lyophilisates prove the suitability of the obtained forms for immediate release systems.

  • Open Access

    Interpolymer Complexes Based on Eudragit® EPO/Eudragit® S100 as Carriers for Oral Controlled Drug Delivery Systems

    by A. V. Bukhovets, A. Y. Sitenkov, R. I. Moustafine

    Интерполимерные комплексы на основе Eudragit® EPO/Eudragit® S100 как перспективные носители для пероральных систем контролируемой доставки